English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Heart failure remains a global burden for patients with established cardiovascular (CV) disease. It has been postulated that underlying mechanisms of nature evolution of HF might be identified by a measurement of some biomarker level that reflects various pathophysiological stages of cardiac dysfunction evolution. On this way, cardiac biomarkers, which affect biomechanical stress, cardiac injury, fluid overload, inflammatory reaction, may be useful tool for prediction of development, progression, and prognosis of HF. The short communication is depicted to a discussion around perspectives to use in routine HF clinical practice new biomarkers, i.e. procalcitonin, copeptin, heart-type fatty acid-binding protein; growth differentiation factor 15. It has concluded that these biomarkers are needed to be investigated in details, while there is suggestion that multiple biomarker models would be better in prediction HF evolution and outcomes than even single brand new biomarker.

Are Novel Cardiac Biomarkers Required in Prediction of Heart Failure Development and Outcomes?